PUMA
1.3.2022 10:02:11 CET | Business Wire | Press release
Sports company PUMA and global leak-proof apparel company Modibodi® have teamed up to launch a range of leak-free period underwear and activewear, created to help women stay comfortable and active during their period whilst making a positive environmental impact.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220301005090/en/
PUMA together with Modibodi believes that everybody who wants to participate in exercise or sport should be given the opportunity to stay active and play, fueling the motivation behind PUMA x Modibodi’s exclusive global partnership under the “She Moves Us” platform.
“Even in the 21st century, periods and leaks still prevent women from participating in sports. Studies have revealed that girls’ participation in sport drops from 69% (ages 11-12) to 45% (ages 13-15)*. Additionally, the single-use plastic from disposable products can continue to pollute the environment for hundreds of years,” said Erin Longin, Global Director Run/Train at PUMA. “As a global brand, we felt it important to do our part to address this issue. The PUMA x Modibodi collaboration allows women to stay active, without having to worry about leaks, while reducing their monthly waste from period products.”
Disposable products pollute the environment and are more expensive long term than their reusable, sustainable counterparts. The PUMA x Modibodi collection is designed to be reused and replaces the need for disposable pads, liners and tampons, whilst ensuring women can stay extremely comfortable, odor free and protected from all leaks (not just periods). Modibodi’s proprietary Modifier Technology™ achieves this through its soft top layer, made of merino wool, which wicks moisture and sweat, a quick-drying absorbent microfibre middle layer, that locks away fluid and odor, and an additional waterproof protection in the bottom layer.
“No woman should have to sit on the sidelines of life because they have their period or bladder leaks,” said Kristy Chong, CEO and Founder, Modibodi. “We are thrilled to launch this collection with PUMA and together normalize menstruation and tackle the stigma that women can't be active on their periods or when experiencing any of life’s leaks.”
As part of the launch, PUMA and Modibodi will work with PUMA’s She Moves Us charity partner, Women Win , to donate a bundle pack of five briefs to 500 girls and women in need. This five-pack bundle covers a person for their monthly cycle and will last for up to four years to allow the person to confidently participate in sport and life without life’s leaks getting in the way.
The first PUMA x Modibodi active underwear collection will be available in May 2022 in selected stores and online at puma.com and modibodi.com.
*Observatory for Sport in Scotland (OSS) https://oss.scot/sport-participation-in-scotland-trends-and-future-prospects/
PUMA
PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 70 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 14,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
MODIBODI
Founded in 2013, Modibodi® is Australia’s original leak-proof apparel brand, designing underwear, swimwear, active wear, maternity wear and reusable nappies to replace disposable hygiene products and offer a sustainable solution to manage periods, incontinence, discharge, breast milk leaks, sweat and more. Modibodi is warm, authentic and human. We help people with all kinds of leaky bodies get on with their lives. We’re plain speaking and taboo breaking. We’re comfortable in our own skin and not embarrassed to talk about leaky bodies – because they’re part of life. We offer a range of products and sizes across our three brands: Modibodi®, Modibodi RED for tweens and teens, and Modibodi Men to manage incontinence, sweat and chafing. Our Modibodi leak-proof products have been scientifically tested and proven to absorb fluid, resist odour, and keep you dry, thanks to the brand’s patented technology which keeps you feeling comfortable and confident and reduces the impact on the environment. Modibodi is committed to sustainability and social impact, helping end period poverty and normalising conversations about periods and leaks through education and supporting people in need globally. To date, Modibodi has sold millions of garments worldwide, saving billions of single-use disposable hygiene products such as pads, liners and tampons from ending up in landfill.
Changing the world should be as easy as changing your underwear. Waste-free, leak-free, worry-free protection.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220301005090/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
